4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (Nasdaq: FDMT), a leader in genetic medicines, has announced its participation in key investor conferences in June 2024. The company will be represented at the Jefferies Global Healthcare Conference on June 6 at 2:30 p.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 2:00 p.m. ET. These events will feature fireside chats and one-on-one meetings with the management team. Archived webcasts of these presentations will be available for up to a year on the 4DMT website for interested investors.
- 4DMT's participation in major healthcare conferences potentially increases visibility and investor engagement.
- Fireside chats and one-on-one meetings provide opportunities for strategic discussions and networking.
- Archived webcasts offer extended access to presentation materials, aiding in long-term investor relations.
- The press release does not mention any new financial or clinical data which may be expected by investors.
- No immediate business developments or strategic announcements were highlighted, potentially leading to investor uncertainty.
- The lack of detailed updates on pipeline progress might concern stakeholders looking for evidence of clinical advancements.
EMERYVILLE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in June. Members of the management team will also be available for one-on-one meetings.
Jefferies Global Healthcare Conference
Presentation Date: | Thursday, June 6, 2024 |
Presentation Time: | 2:30 p.m. ET |
Webcast Link: | Webcast |
45th Annual Goldman Sachs Global Healthcare Conference
Presentation Date: | Tuesday, June 11, 2024 |
Presentation Time: | 2:00 p.m. ET |
Webcast Link: | Webcast |
Archived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine help us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT®, 4D®, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine Smith
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Communications
Investor.Relations@4DMT.com
FAQ
What are the dates for 4DMT's presentations at the upcoming conferences?
At what time will 4DMT's presentations take place?
How can I access the webcasts of 4DMT's conference presentations?
What is the stock symbol for 4D Molecular Therapeutics?